Active

VIVES II - Louvain Technology Fund

Switched

BE0838819178

Rechtspersoon Public limited company

Place de l'Université 16, 1348 Ottignies-Louvain-la-Neuve

Active for

15 year

Financials

Financial year 2025

Gross margin

€ -22,791

▲ 54% vs 2024

Profit

Growing

€ 3.5 million

▲ 172% vs 2024

Debts

Low

€ 12,409

▼ 45% vs 2024

VIVES II - Louvain Technology Fund from Ottignies-Louvain-la-Neuve, company number BE0838819178, closed financial year 2025 with a result of € 3.5 million after tax. For that financial year VIVES II - Louvain Technology Fund recorded a gross margin of € -22,791 and equity of € 7.7 million. Compared with financial year 2024, the result moved from € -4.9 million to € 3.5 million. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.

What happened at VIVES II - Louvain Technology Fund?

What happened at VIVES II - Louvain Technology Fund in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • Vives Partners SRL stepped down as director. NBB
  • New annual accounts for financial year 2025: profit of € 3.5 million. Source: NBB ↗
  • IRD SA stepped down as director. NBB
  • ING Belgique stepped down as director. NBB
  • BPI France Investissement stepped down as director. NBB
  • Invest.Bw stepped down as director. NBB
  • Pascal Dumont stepped down as director. NBB
  • SFPI stepped down as director. NBB

In short

From € 4.7 million profit in 2021 to € 3.5 million profit in 2025.

Best year ever: 2021, with € 4.7 million profit.

A new publication or filing at VIVES II - Louvain Technology Fund? We notify you, reason included.

Follow VIVES II - Louvain Technology Fund

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

VIVES II - Louvain Technology Fund
Tessares 28.3%
Axinesis 25.4%
Botalys 11.6%
+3

It owns 28.3% of Tessares, 25.4% of Axinesis, 12.5% of Novadip Biosciences , 11.6% of Botalys, 9.8% of Virovet and 3.5% of Aphea.Bio itself.

See the full network in the app

Directors

According to the 2025 annual accounts

IRD SA

Director · represented by Hélène Guillon épouse Cannard

since 2021 · until 2026

Vives Partners SRL

Managing director · represented by Philippe Durieux

Also active at: NOVADIP BIOSCIENCES, TESSARES, AXINESIS +9 more

since 2024 · until 2026

since 2021 · until 2026

BPI France Investissement

Director · represented by Sandra Goussu

since 2021 · until 2026

Invest.Bw

Director · represented by Pierre de Waha Baillonville

Also active at: SOCIETE D'ASSAINISSEMENT ET DE RENOVATION DES SITES INDUSTRIELS DU BRABANT WALLON, SYBERMAT, SCALE UP +28 more

since 2021 · until 2026

Pascal Dumont

Director

Also active at: THEODORUS III

since 2021 · until 2026

since 2021 · until 2026

Didier Lamote

Director

Also active at: Capricorn SCF, SDG Frontier Fund, CAPRICORN HEALTH-TECH FUND

since 2022 · until 2026

Jean-François Burguet

Director

since 2021 · until 2025

Charles de Lidekerke

Chairman of the board

since 2021 · until 2026

Establishments

Establishment units

Physical locations of this company

Registered office

Place de l'Université 16 box 27

1348 Ottignies-Louvain-la-Neuve

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 26 companies are registered at this address.

+21 more

Details

Company number
0838.819.178
VAT number
BE 0838.819.178
Registered office
Place de l'Université 16 bus 27, 1348 Ottignies-Louvain-la-Neuve
Names & denominations
VIVES II - Louvain Technology Fund · VIVES II
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
25 August 2011
Peppol
Not registered

Frequently asked questions

What is the enterprise number of VIVES II - Louvain Technology Fund?
The enterprise number of VIVES II - Louvain Technology Fund is BE0838819178.
What is the address of VIVES II - Louvain Technology Fund?
The registered office of VIVES II - Louvain Technology Fund is located at Place de l'Université 16 box 27, 1348 Ottignies-Louvain-la-Neuve.
When was VIVES II - Louvain Technology Fund founded?
VIVES II - Louvain Technology Fund was founded on 25 August 2011.
Does VIVES II - Louvain Technology Fund have a website?
No website is currently known for VIVES II - Louvain Technology Fund.
How much profit did VIVES II - Louvain Technology Fund make in 2025?
VIVES II - Louvain Technology Fund posted a profit after taxes of € 3,489,304 in financial year 2025.
What is the revenue of VIVES II - Louvain Technology Fund?
As a small company, VIVES II - Louvain Technology Fund is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -22,791.
Where can I find the annual accounts of VIVES II - Louvain Technology Fund?
VIVES II - Louvain Technology Fund files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of VIVES II - Louvain Technology Fund?
According to the 2025 annual accounts, the directors of VIVES II - Louvain Technology Fund are: IRD SA, Vives Partners SRL , ING Belgique, BPI France Investissement, Invest.Bw, Pascal Dumont, SFPI, Didier Lamote.
Who owns VIVES II - Louvain Technology Fund?
It owns 28.3% of Tessares, 25.4% of Axinesis, 12.5% of Novadip Biosciences , 11.6% of Botalys, 9.8% of Virovet and 3.5% of Aphea.Bio itself.